Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2017-01-12

Clinical Trial Update: Effects of Labetalol on Nicotine Administration in Humans - 14 [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating the effects of the beta-blocker labetalol on nicotine administration for tobacco use disorder has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • labetalol (labetalol hydrochloride)

Snippet

Sponsor: National Institute on Drug Abuse (NIDA) | Conditions: Tobacco Use Disorder | Phase 2 | Status: COMPLETED